Vitamin D3 supplementation improves serum SFRP5 and Wnt5a levels in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial

2018 ◽  
Vol 88 (1-2) ◽  
pp. 73-79 ◽  
Author(s):  
Farzaneh Rezagholizadeh ◽  
Seyed Ali Keshavarz ◽  
Mahmoud Djalali ◽  
Esmaeel Yussefi Rad ◽  
Shahab Alizadeh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vitamin D ◽  
Vitamin D3 ◽  
Integration Site ◽  
Fasting Blood Glucose ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Tnf Α ◽  
Vitamin D3 Supplementation

Abstract. Objective: To explore the effect of vitamin D3 on novel serum adipokines, secreted frizzled-related protein 5 (SFRP5) and Wingless-Type MMTV Integration Site Family Member 5a (Wnt5a) levels in Type 2 Diabetes Mellitus (T2DM) patients. Methods: Forty patients (16 women and 24 men) with type 2 diabetes participated in this double-blind, randomized, placebo-controlled clinical trial study. Participants were randomly assigned to receive 4000 IU vitamin D3 (n = 20) or placebo (n = 20) daily for 2 months. Anthropometric indices, fasting blood glucose (FBS), hemoglobin A1c (HbA1c), insulin, serum tumor necrosis factor (TNF)-α, Wnt5a, SFRP5, physical activity, lipid profile, dietary intake, and serum calcidiol were assessed at the baseline and after 8 weeks. Results: In the group receiving Vitamin D, a significant increase in Calicidiol (15.03 ± 10.44 vs. 27.33 ± 11.2 ng/dl; P = < 0.001), SFRP5 (3.6 ± 0.46 vs. 3.98 ± 0.59 ng/ml; P = 0.01), and Wnt5a (0.33 ± 0.129 vs. 0.29 ± 0.047; P = 0.03) was observed. After two months supplementation, there were significant between-group differences in Calicidiol (27.33 ± 11.2 vs. 17.9 ± 12.95 ng/dl; P = 0.01), TNF-α (89.22 ± 34.28 vs. 164.93 ± 120.45 ng/ml; P = 0.006), Wnt5a (0.29 ± 0.047 vs. 0.33 ± 0.09; P = 0.04), and HbA1c (6.6 ± 0.96 % vs. 7.64 ± 1.15 %; p = 0.002). Moreover, the net changes (end – baseline) of Calicidiol (P = < 0.001), SFRP5 (P = 0.04), Wnt5a (P = 0.005), TNF-α (P = 0.01), insulin (P = 0.03), and QUICKI (P = 0.01) was significant between the groups. There were no significant effects on FBS and homeostasis model of assessment-estimated insulin resistance (HOMA-IR). Conclusion: 8 weeks of vitamin D3 supplementation for patients with type 2 diabetes may increase serum anti-inflammatory adipokine SFRP5 but decrease serum pro-inflammatory Wnt5a and TNF-α.

scholarly journals Effects of cinnamon supplementation on expression of systemic inflammation factors, NF-kB and Sirtuin-1 (SIRT1) in type 2 diabetes: a randomized, double blind, and controlled clinical trial

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
Mina Davari ◽  
Reza Hashemi ◽  
Parvin Mirmiran ◽  
Mehdi Hedayati ◽  
Shamim Sahranavard ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Sirtuin 1 ◽  
Controlled Clinical Trial ◽  
Group Comparison ◽  
Double Blind ◽  
Tnf Α ◽  
Significant Difference ◽  
Hs Crp

Abstract Background and objectives NF-kB, SIRT1 and systemic inflammation factors including hs-CRP, IL-6 and TNF-α accelerate atherosclerosis pathogenesis. Our purpose was to evaluate the effect of daily supplementation of three-gram cinnamon on plasma levels of NF-kB, SIRT, hs-CRP, IL-6 and TNF-α among type 2 diabetes patients. Subjects and methods A randomized, double blind, and controlled clinical trial was performed with 44 adult patients who were 25 to 70 years old with type 2 diabetes, randomized to two intervention (n = 22) and control (n = 22) groups differing by daily three grams cinnamon supplementation and placebo for 8 weeks, respectively. The plasma levels of NF-kB, SIRT, hs-CRP, IL-6 and TNF-α were measured by ELISA assay at the beginning and end of the study. Results After 8-week intervention, 39 subjects (n = 20 in the cinnamon and n = 19 in the placebo groups) ended up the trial. It was not observed significant difference in levels of hs-CRP (P = 0.29), TNF-α (P = 0.27), IL-6 (P = 0.52), and Sirtuin-1 (P = 0.51) in between group comparison. While, the result showed significant difference in levels of NF-kB (P = 0.02) between groups. As well as, in among group comparison, there was not observed significant differences except in hs-CRP (P = 0.008) in placebo group. Conclusions This study elucidated that cinnamon supplementation has no beneficial effects in reduction of NF-kB, SIRT1, hs-CRP, IL-6 and TNF-α levels in type 2 diabetes patients which have a considerable role in development of atherogenesis.

scholarly journals Calcium-Vitamin D Cosupplementation Influences Circulating Inflammatory Biomarkers and Adipocytokines in Vitamin D-Insufficient Diabetics: A Randomized Controlled Clinical Trial

2014 ◽  
Vol 99 (12) ◽  
pp. E2485-E2493 ◽  
Author(s):  
Maryam Tabesh ◽  
Leila Azadbakht ◽  
Elham Faghihimani ◽  
Marjan Tabesh ◽  
Ahmad Esmaillzadeh
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Vitamin D ◽  
Vitamin D Supplementation ◽  
Inflammatory Biomarkers ◽  
Hypoglycemic Agents ◽  
Controlled Clinical Trial ◽  
Diabetic Patients ◽  
Tnf Α

Context: To the best of our knowledge, no study has examined the effects of vitamin D-calcium cosupplementation on inflammatory biomarkers and adipocytokines in vitamin D-insufficient type 2 diabetics. Objective: This study was performed to assess the effects of vitamin D and calcium supplementation on inflammatory biomarkers and adipocytokines in vitamin D-insufficient people with type 2 diabetes. Methods: Totally, 118 diabetic patients were enrolled in this randomized, placebo-controlled clinical trial. After matching for age, sex, body mass index, type and dose of hypoglycemic agents, and duration of diabetes, subjects were randomly assigned into 4 groups receiving the following: 1) 50000 IU/wk vitamin D + calcium placebo; 2) 1000 mg/d calcium + vitamin D placebo; 3) 50 000 IU/wk vitamin D + 1000 mg/d calcium; or 4) vitamin D placebo + calcium placebo for 8 weeks. Blood sampling was done for the quantification of inflammatory biomarkers and adipocytokines at the study baseline and after 8 weeks of intervention. Results: Calcium (changes from baseline: −75±19 ng/ml, P = .01) and vitamin D alone (−56 ± 19 ng/mL, P = .01) and joint calcium-vitamin D supplementation (−92 ± 19 ng/mL, P = .01) resulted in a significant reduction in serum leptin levels compared with placebo (−9 ± 18 ng/mL). This was also the case for serum IL-6, such that calcium (−2 ± 1 pg/mL, P &lt; .001) and vitamin D alone (−4 ± 1 pg/mL, P &lt; .001) and their combination (−4 ± 1 pg/mL, P &lt; .001) led to significant reductions compared with placebo (3 ± 1 pg/mL). After adjustment for potential confounders, individuals in the calcium (−3.1 ± 1.3, P &lt; .05), vitamin D (−3.1 ± 1.3, P &lt; .05), and joint calcium-vitamin D groups (−3.4 ± 1.3, P &lt; .05) had greater reductions in serum TNF-α concentrations compared with placebo (0.1 ± 1.2). Individuals who received joint calcium-vitamin D supplements tended to have a decrease in serum high-sensitivity C-reactive protein levels compared with placebo after controlling for baseline levels (−1.14 ± 0.25 vs 0.02 ± 0.24 ng/mL, P = .09). Conclusion: Joint calcium-vitamin D supplementation might improve systemic inflammation through decreasing IL-6 and TNF-α concentrations in vitamin D-insufficient people with type 2 diabetes.

scholarly journals Influence of Lactobacillus paracasei HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial

Foods ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1455
Author(s):  
Parichart Toejing ◽  
Nanticha Khampithum ◽  
Sasithorn Sirilun ◽  
Chaiyavat Chaiyasut ◽  
Narissara Lailerd
Keyword(s):  
Type 2 Diabetes ◽  
Placebo Group ◽  
Pathogenic Bacteria ◽  
Corn Starch ◽  
Fasting Blood Glucose ◽  
Controlled Study ◽  
Double Blind ◽  
Tnf Α ◽  
To Receive

It has been shown that gut dysbiosis can be associated with the development of type 2 diabetes mellitus (T2DM). Consequently, intervention with probiotics may be a useful approach to improve metabolic variables in diabetes. The present study aimed to evaluate the efficacy of L. paracasei HII01 on glycemia in T2DM patients. In a randomized, double-blind, placebo-controlled study, 50 participants were allocated to receive L. paracasei HII01 (50 × 109 CFU/day) or a placebo (corn starch 10 mg/day). Blood and fecal samples were assessed at baseline and at the end of the trial. After 12 weeks of intervention, fasting blood glucose level had significantly decreased in the probiotic group compared with the placebo group. Importantly, probiotic supplementation significantly decreased the plasma levels of LPS, TNF-α, IL-6 and hsCRP compared the placebo group. Additionally, an increase in beneficial bacteria and a decrease in pathogenic bacteria, which related to the improvement of SCFAs, was found following L. paracasei HII01 supplementation. These findings demonstrated that L. paracasei HII01 improved hyperglycemia and inflammatory markers by favorably modifying gut microbiota and subsequently ameliorating the leaky gut and endotoxemia, thereby suggesting a potential role as an adjuvant treatment in type 2 diabetes.

scholarly journals Efficacy of Pomegranate Seed Powder on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes: A Prospective Randomized Double-Blind Placebo-Controlled Clinical Trial

2020 ◽  
pp. 1-8
Author(s):  
Monire Seyed Hashemi ◽  
Nasim Namiranian ◽  
Hemaseh Tavahen ◽  
Abolfazl Dehghanpour ◽  
Mohammad Hadi Rad ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Placebo Group ◽  
Fasting Blood Glucose ◽  
Antidiabetic Activity ◽  
Controlled Clinical Trial ◽  
Complementary Treatment ◽  
Double Blind ◽  
Pomegranate Seed Powder ◽  
Pomegranate Seed

<b><i>Introduction:</i></b> Pomegranate is known as a functional food which has multiple health-promoting activities. It has been assessed for patients with metabolic syndrome. Specifically, an antidiabetic activity of its juice and plausible mechanisms for its action have been shown in multitudinous studies. The aim of this study was assessing the effects of complementary treatment with pomegranate seed powder (PSP) oral supplementation on patients with type 2 diabetes mellitus (T2DM). <b><i>Methods:</i></b> Sixty patients were treated for 8 weeks by 5 g PSP or placebo, twice daily. Fasting blood glucose (FBG), glycated hemoglobin (HbA<sub>1c</sub>), total cholesterol, and triglyceride (TG) were recorded as the outcome measures at the beginning and after the intervention. The findings were analyzed using the independent <i>t</i> test and Mann-Whitney U test. <b><i>Results:</i></b> After 8 weeks, the mean differences of FBG, HbA<sub>1c</sub>, cholesterol, and TG were significantly decreased in the PSP group when compared with the placebo group (<i>p</i> value &#x3c;0.05). In addition, post-intervention values of FBG and HbA<sub>1c</sub> were significantly lower in patients treated with PSP compared to the placebo group (<i>p</i> values = 0.02 and 0.01, respectively). However, the latter comparison regarding cholesterol and TG showed no significant differences (<i>p</i> values = 0.51 and 0.26, respectively). <b><i>Conclusion:</i></b> It seems that complementary treatment with PSP may have beneficial effects on FBG and HbA<sub>1c</sub> of patients with T2DM. However, its effect on TG and cholesterol was equivocal.

scholarly journals Effect of vitamin D3 supplementation on insulin resistance and β-cell function in prediabetes: a double-blind, randomized, placebo-controlled trial

2019 ◽  
Vol 110 (5) ◽  
pp. 1138-1147 ◽  
Author(s):  
Helen J Wallace ◽  
Lauren Holmes ◽  
Cieran N Ennis ◽  
Christopher R Cardwell ◽  
Jayne V Woodside ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Vitamin D ◽  
Vitamin D3 ◽  
Cell Function ◽  
Controlled Trial ◽  
Β Cell ◽  
Double Blind ◽  
Vitamin D3 Supplementation ◽  
Β Cell Function

ABSTRACT Background Observational studies have suggested an inverse association between low serum 25-hydroxyvitamin D [25(OH)D] concentrations and development of type 2 diabetes. High-quality trials are required to test the hypothesis that vitamin D is a direct contributor to type 2 diabetes pathogenesis. Objective The purpose of this double-blind randomized placebo-controlled trial was to investigate the effect of vitamin D3 supplementation on insulin resistance (IR) and β-cell function in people with prediabetes and suboptimal vitamin D status (<50 nmol/L). Methods Sixty-six individuals were randomly assigned to receive 3000 IU (75 µg) vitamin D3 or placebo daily for 26 wk. Compliance was monitored by pill count and change in serum 25(OH)D concentration using LC-MS. The primary endpoint was between-group difference in change in IR assessed using a 2-step euglycemic–hyperinsulinemic clamp combined with infusion of tritiated glucose. An oral-glucose-tolerance test was performed pre- and postintervention to calculate indices of β-cell function. Between-group comparisons were made using ANCOVA. Results In total, 64 participants completed the study. Baseline serum 25(OH)D concentrations in the vitamin D3 and placebo group were 30.7 and 30.0 nmol/L, with status increasing by 70.5 nmol/L and 5.3 nmol/L, respectively (between-group difference in vitamin D: 65.8 nmol/L; 95% CI: 54.2, 77.3 nmol/L; P < 0.01), after supplementation. There was no difference between groups in measures of whole-body, peripheral, or hepatic IR or in any measure of glycemic control or β-cell function. Conclusion This study employed a robust assessment of IR and β-cell function and targeted a high-risk population with low 25(OH)D status at baseline and found that vitamin D3 supplementation had no effect on insulin action in people with prediabetes. This trial was registered on clinicaltrials.gov as NCT01889810.

scholarly journals Safety and Tolerability of Vitamin D Supplementation in the Vitamin D and Type 2 Diabetes (D2d) Study – A Randomized Trial in Persons With Prediabetes

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 1318-1318
Author(s):  
Karen Johnson ◽  
Anastassios Pittas ◽  
Karen Margolis ◽  
Anne Peters ◽  
Lawrence Phillips ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vitamin D ◽  
Vitamin D3 ◽  
Kidney Diseases ◽  
The United States ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Medication Incident ◽  
Vitamin D3 Supplementation

Abstract Objectives The routine use of vitamin D supplements has increased substantially in the United States. However, the safety and tolerability of long-term use of high-dose vitamin D are unknown. We assessed the safety and tolerability of vitamin D3 at a dose of 4000 IU daily in the vitamin D and type 2 diabetes (D2d) trial. Methods Persons with overweight/obesity and prediabetes without a recent history of nephrolithiasis, hypercalcemia, hypercalciuria, or other conditions potentially associated with vitamin D use, were randomized to either daily 4000 IU of vitamin D3 or placebo. Participants were allowed to take vitamin D up to 1000 IU/day and calcium up to 600 mg/day, in addition to study medication. Incident adverse events (AE), defined as any untoward or unfavorable medical occurrence, were ascertained in both groups at in-person visits and interim phone or email encounters four times a year. Serious AEs (SAE) were defined as those AEs that resulted in death, new or prolonged hospitalization, persistent or significant disability, or congenital anomaly or birth defect, or were life threatening or represented another significant hazard. Results A total of 8,304 AEs occurred during three years of follow-up. AEs were less frequent in the vitamin D group compared to placebo [4039 (116.1 events per 100 person-years) vs. 4265 (123.8 events per 100 person-years) (Incidence Rate Ratio [IRR] = 0.94; 95% Confidence Interval (CI) 0.90, 0.98)]. The overall frequency of protocol-specified AEs of interest was low, including nephrolithiasis, hypercalcemia, hypercalciuria, and low estimated glomerular filtration rate (eGFR) with no significant between-group differences. There were also no significant differences between the vitamin D and placebo groups in SAEs (IRR = 0.95; 95% CI 0.81, 1.13). Conclusions Vitamin D3 supplementation at 4,000 IU per day was safe and well-tolerated and did not increase risk of AEs or SAEs, including those typically associated with vitamin D excess such as hypercalciuria or nephrolithiasis. Funding Sources National Institute of Diabetes and Digestive and Kidney Diseases, Office of Dietary Supplements of the National Institutes of Health, the American Diabetes Association.

Sign in / Sign up

Export Citation Format

Share Document